Kynam Capital Management, LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001907884

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2024 · 26 positions · Total reported value $1.30B · Top-10 concentration 81.9% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 48.8% · 4 new · 7 cut · 9 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +14.0% · vs SPY -0.8% · Prev Value $1.55B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2024 13F filing, Kynam Capital Management, LP disclosed 26 equity positions with a combined reported value of $1.30B. The filing implies a focused portfolio: its ten largest positions account for 81.9% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2024 were NTRA ($218.14M), VRTX ($154.68M), CLDX ($125.43M). By sector, the heaviest allocations are Health Care 83.4%, Other 16.6%. Versus the prior quarter, allocation shifted toward Other (+7.5pp) and away from Health Care (-7.5pp).

Versus the prior quarter, Kynam Capital Management, LP opened 4 new positions, trimmed 7 and fully exited 9, a turnover rate of 48.8% of positions. The portfolio's overlap with the prior quarter was 81% of names.

The largest new positions opened in Q2 2024 were SPY ($109.10M), INSM ($67.00M), ALNY ($10.45M).

Of the 9 positions fully exited versus the prior quarter, the largest were CORT ($14.76M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2024)

  • SPY STATE STR SPDR S&P 500 ETF T · $109.10M
  • INSM INSMED INC · $67.00M
  • ALNY ALNYLAM PHARMACEUTICALS INC · $10.45M
  • CGON CG ONCOLOGY INC · $1.70M

Fully Exited (vs previous quarter)

  • CORT CORCEPT THERAPEUTICS INC · prev qtr: $14.76M

Insider Transactions (Form 4)

Latest Kynam Capital Management, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Kynam Capital Management, LP files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 32 positions worth $1.81B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • SEC registration: 801-126187 (status: Approved), registered 2022-07-22
  • Regulatory AUM (Form ADV): $2.41B as of 2026-04-10
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 1 private funds, of which 1 hedge funds

Portfolio Structure

  • 32 positions · $1.81B reported value (Q2 2026)
  • Top 10 holdings = 72.7% of reported value
  • Largest position: CLDX (CELLDEX THERAPEUTICS INC NEW) at 10.9%
  • Average position size: $56.54M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 4 new, 12 added, 7 reduced, 9 exited
  • 9 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 83.4%
Other 16.6%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.01M $218.14M 16.83%
16.83%
Add
2 330.00K $154.68M 11.93%
11.93%
Add
3 3.39M $125.43M 9.68%
9.68%
Add
4 5.72M $117.47M 9.06%
9.06%
Add
5 200.00K $109.10M 8.41%
8.41%
New
6 7.08M $79.54M 6.13%
6.13%
Add
7 9.26M $78.07M 6.02%
6.02%
Add
8 1.00M $67.00M 5.17%
5.17%
New
9 753.24K $56.88M 4.39%
4.39%
Add
10 1.54M $55.85M 4.31%
4.31%
Add
11 8.83M $54.55M 4.21%
4.21%
Add
12 800.00K $27.72M 2.14%
2.14%
Reduce
13 5.95M $22.92M 1.77%
1.77%
Hold
14 1.75M $22.77M 1.76%
1.76%
Add
15 3.98M $19.84M 1.53%
1.53%
Add
16 2.02M $16.62M 1.28%
1.28%
Add
17 916.57K $11.00M 0.85%
0.85%
Reduce
18 1.64M $10.71M 0.83%
0.83%
Add
19 43.00K $10.45M 0.81%
0.81%
New
20 566.72K $9.06M 0.70%
0.70%
Add
21 12.16M $8.36M 0.65%
0.65%
Add
22 974.67K $6.28M 0.48%
0.48%
Reduce
23 2.02M $5.93M 0.46%
0.46%
Add
24 831.31K $3.67M 0.28%
0.28%
Add
25 1.65M $2.70M 0.21%
0.21%
Add
26 53.91K $1.70M 0.13%
0.13%
New

FAQ

What did Kynam Capital Management, LP buy in 2024-Q2?

In its 2024-Q2 13F filing, Kynam Capital Management, LP reported 26 equity positions worth $1.30B in aggregate; its largest disclosed positions were NTRA ($218.14M), VRTX ($154.68M), CLDX ($125.43M).

How large is Kynam Capital Management, LP's portfolio?

Kynam Capital Management, LP reported $1.30B of long equity holdings across 26 positions as of 2024-Q2. Top-10 holdings account for 81.9% of reported value.

What is Kynam Capital Management, LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/kynam-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →